Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Surgery

Launched by FUNDACIN BIOMEDICA GALICIA SUR · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a program of physical exercise and respiratory therapy can help patients prepare for and recover from bariatric surgery, which is a procedure to help with weight loss for people who are obese. The researchers want to find out if this program can help prevent complications, reduce risks during surgery, and allow patients to leave the hospital sooner. They will also look at how exercise might affect certain biological markers related to obesity and liver health.

To participate, you need to be between 18 and 69 years old and scheduled for bariatric surgery at the Álvaro Cunqueiro Hospital in Vigo. If you join the study, you will be randomly assigned to either follow the exercise and therapy program or to continue with the usual care before and after your surgery. Importantly, you will need to provide consent to join the trial, and there are some reasons you may not be eligible, such as if you have certain medical conditions or if you are unable to understand the study. This trial is not yet recruiting participants, but it aims to gather important information that could improve care for future bariatric surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing bariatric surgery at the General and Digestive Surgery Department of the Álvaro Cunqueiro Hospital in Vigo.
• • Be over 18 and under 69 years old.
• • Sign the informed consent to participate in the study.
• Exclusion Criteria:
• • Patient's refusal to enter the study.
• • Inability to comprehend participation in a study.
• • Urgent interventions.
• • Patients undergoing combined surgery with another surgical service.
• • Patients who cannot read and write or are dependent on a legal representative.
• • Patients on treatment for diabetes with GLP-1 agonists (glucagon-like peptide type 1 agonists) and/or SGLT2 inhibitors (sodium-glucose cotransporter type 2 inhibitors) whose dose is not stable in the last 3 months.